Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 6/20 | 0.54 |
| ▸ | CES1 | P23141 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | LPAR1 | Q92633 | 7/20 | 0.50 |
| ▸ | FABP3 | P05413 | 5/20 | 0.50 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.50 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.50 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.50 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1367614 | 1.00 | FAAH (0.54) | FAAHCES1MEN1TP53CYP1A2 | |
| SCHEMBL25868 | 0.91 | FAAH (0.46) | FAAHCES1MEN1CYP1A2KMT2A | |
| SCHEMBL2782415 | 0.91 | FAAH (0.46) | FAAHCES1MEN1CYP1A2KMT2A | |
| SCHEMBL2783090 | 0.91 | FAAH (0.46) | FAAHCES1MEN1CYP1A2KMT2A | |
| SCHEMBL1417477 | 0.78 | FAAH (0.58) | FAAHCES1MEN1TP53CYP1A2 | |
| SCHEMBL6510863 | 0.78 | LPAR3 (0.47) | FAAHMEN1TP53CYP1A2CYP3A4 | |
| SCHEMBL28857015 | 0.78 | FAAH (0.58) | FAAHCES1MEN1TP53CYP1A2 | |
| SCHEMBL466646 | 0.77 | FAAH (0.51) | FAAHCES1MEN1TP53CYP1A2 | |
| SCHEMBL466851 | 0.77 | FAAH (0.51) | FAAHCES1MEN1TP53CYP1A2 | |
| SCHEMBL466712 | 0.77 | FAAH (0.51) | FAAHCES1MEN1TP53CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12350369-B2 | Serial filtration to generate small cholesterol-containing liposomes | VERILY LIFE SCIENCES LLC (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250026770-A1 | NOVEL BORONSOME FACILITATING DIAGNOSIS AND TREATMENT | PEKING UNIVERSITY (CN) | 2025-01-23 | — | — | US | disclosed |
| EP-4446328-A1 | NOVEL BORONSOME FACILITATING DIAGNOSIS AND TREATMENT | Peking University (CN) | 2024-10-16 | — | — | EP | disclosed |
| US-20240268396-A1 | VESICLE FORMULATIONS FOR DELIVERY OF ANTIFUNGAL NUCLEIC ACIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-08-15 | — | — | US | disclosed |
| EP-4355098-A1 | VESICLE FORMULATIONS FOR DELIVERY OF ANTIFUNGAL NUCLEIC ACIDS | The Regents of the University of California (US) | 2024-04-24 | — | — | EP | disclosed |
| WO-2022266385-A1 | VESICLE FORMULATIONS FOR DELIVERY OF ANTIFUNGAL NUCLEIC ACIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-12-22 | — | — | WO | disclosed |
| US-20220193108-A1 | Immunotherapeutic Nanoparticles And Methods Relating Thereto | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2022-06-23 | — | — | US | disclosed |
| US-20220105037-A1 | SERIAL FILTRATION TO GENERATE SMALL CHOLESTEROLCONTAINING LIPOSOMES | VERILY LIFE SCIENCES LLC (US) | 2022-04-07 | — | — | US | disclosed |
| US-11246832-B2 | Serial filtration to generate small cholesterol-containing liposomes | VERILY LIFE SCIENCES LLC (US) | 2022-02-15 | — | — | US | disclosed |
| US-20210290537-A1 | LIPOSOMAL ELINAFIDE FORMULATIONS AND USES THEREOF | MALLINCKRODT LLC (US) | 2021-09-23 | — | — | US | disclosed |
| US-20180344644-A1 | IMPROVED STABILITY OF LIPOSOME FORMULATIONS AND USES THEREOF | IKARIA THERAPEUTICS LLC | 2018-12-06 | — | — | US | disclosed |
| EP-3352733-A1 | IMPROVED STABILITY OF LIPOSOME FORMULATIONS AND USES THEREOF | Mallinckrodt LLC (US) | 2018-08-01 | — | — | EP | disclosed |
| WO-2018106980-A1 | LIPOSOMAL ELINAFIDE FORMULATIONS AND USES THEREOF | MALLINCKRODT LLC (US) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018089481-A1 | MITOMYCIN C PRODRUG LIPOSOME FORMULATIONS AND USES THEREOF | MALLINCKRODT LLC (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018005657-A1 | SERIAL FILTRATION TO GENERATE SMALL CHOLESTEROL-CONTAINING LIPOSOMES | VERILY LIFE SCIENCES LLC (US) | 2018-01-04 | — | — | WO | disclosed |
| WO-2017053464-A1 | IMPROVED STABILITY OF LIPOSOME FORMULATIONS AND USES THEREOF | MALLINCKRODT LLC (US) | 2017-03-30 | — | — | WO | disclosed |
| US-20160250177-A1 | MODIFIED DOCETAXEL LIPOSOME FORMULATIONS AND USES THEREOF | MALLINCKRODT US POOL LLC | 2016-09-01 | — | — | US | disclosed |
| US-20140271822-A1 | MODIFIED DOCETAXEL LIPOSOME FORMULATIONS | MALLINCKRODT LLC (US) | 2014-09-18 | — | — | US | disclosed |
| EP-2217208-A2 | NUCLEIC ACID COMPLEX AND NUCLEIC ACID DELIVERY COMPOSITION | Otsuka Pharmaceutical Co., Ltd. (JP) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009061003-A2 | NUCLEIC ACID COMPLEX AND NUCLEIC ACID DELIVERY COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180344644-A1 | IMPROVED STABILITY OF LIPOSOME FORMULATIONS AND USES THEREOF | SGMS2, SGMS1, LIPA | FAAH 1266/4885CES1 1376/4885MEN1 586/4885 |
| US-20140271822-A1 | MODIFIED DOCETAXEL LIPOSOME FORMULATIONS | SGMS2, PHOSPHO1, SGMS1 | FAAH 1182/4885CES1 978/4885MEN1 1278/4885 |
| US-20160250177-A1 | MODIFIED DOCETAXEL LIPOSOME FORMULATIONS AND USES THEREOF | LPAR5, LPCAT3, DHCR7 | FAAH 555/4885CES1 737/4885MEN1 1360/4885 |
| US-20250026770-A1 | NOVEL BORONSOME FACILITATING DIAGNOSIS AND TREATMENT | PHOSPHO1, CHMP4B, SGMS1 | FAAH 1331/4885CES1 531/4885MEN1 96/4885 |
| US-20210290537-A1 | LIPOSOMAL ELINAFIDE FORMULATIONS AND USES THEREOF | STARD7, MYOF, MTPN | FAAH 1016/4885CES1 515/4885MEN1 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.